Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Idorsia Ltd    IDIA   CH0363463438

IDORSIA LTD

(IDIA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
32.36(c) 31.34(c) 27.6(c) 26.44(c) 26.04 Last
281 807 402 374 4 054 404 2 353 950 694 585 Volume
+0.50% -3.15% -11.93% -4.20% -1.51% Change
More quotes
Financials
Sales 2020 49,9 M 53,1 M 53,1 M
Net income 2020 -482 M -513 M -513 M
Net Debt 2020 116 M 124 M 124 M
P/E ratio 2020 -7,55x
Yield 2020 -
Sales 2021 49,7 M 52,9 M 52,9 M
Net income 2021 -503 M -535 M -535 M
Net Debt 2021 109 M 116 M 116 M
P/E ratio 2021 -7,62x
Yield 2021 -
Capitalization 3 764 M 4 004 M 4 006 M
EV / Sales 2020 77,7x
EV / Sales 2021 77,9x
Nbr of Employees 650
Free-Float 58,3%
More Financials
Company
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan... 
More about the company
Surperformance© ratings of Idorsia Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on IDORSIA LTD
07/08Johnson & Johnson's Cilag to sell up to 11.8 million Idorsia shares
RE
07/06Idorsia announces positive results in the second Phase 3 study of daridorexan..
GL
05/20Idorsia successfully completes the offering of new shares thereby securing fu..
GL
05/19Idorsia launches an offering of new shares to fund the company's growth plan
GL
05/13Idorsia holds its third Annual General Meeting of Shareholders
GL
05/11IDORSIA : Neurocrine Biosciences Exercises Option to License Idorsia's Novel Tre..
PR
04/23Idorsia announces financial results for the first quarter 2020
GL
04/02Idorsia issues Notice of the 2020 Annual General Meeting of Shareholders
GL
03/19Janssen announces submission of New Drug Application to the U.S. FDA for pone..
GL
03/04Janssen submits European Marketing Authorization Application for ponesimod fo..
GL
02/06Idorsia announces financial results for 2019 – clinical programs advanc..
GL
01/30Invitation to Idorsia's full year financial results 2019 webcast and conferen..
GL
01/13NEUROCRINE BIOSCIENCES : and Idorsia Amend Option Agreement to License Novel Tre..
AQ
01/10Neurocrine Biosciences and Idorsia amend option agreement to license novel tr..
GL
2019Idorsia and Mochida enter into a license agreement for the supply, co-develop..
GL
More news
News in other languages on IDORSIA LTD
07/10ZURICH STOCK EXCHANGE : 4-Wochenvorschau Schweiz
07/09Aktien Schweiz Schluss: US-Ausverkauf setzt dem SMI zu
07/09Aktien Schweiz: SMI verteidigt kleines Plus
07/09Fort repli du titre Idorsia après le désengagement de Cilag Holding
07/09Idorsia-Aktien sacken nach Bericht über Aktienplatzierung zweistellig ab
More news
Chart IDORSIA LTD
Duration : Period :
Idorsia Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IDORSIA LTD
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 35,40 CHF
Last Close Price 26,44 CHF
Spread / Highest target 70,2%
Spread / Average Target 33,9%
Spread / Lowest Target 11,6%
EPS Revisions
Managers
NameTitle
Jean-Paul Clozel Chief Executive Officer & Director
Jean-Pierre Garnier Chairman
André C. Muller Chief Financial Officer & Executive Vice President
Guy Braunstein Head-Global Clinical Development & Executive VP
Martine Clozel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
IDORSIA LTD-11.69%4 004
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955